Compare SLNG & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ANIX |
|---|---|---|
| Founded | 2013 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2M | 100.6M |
| IPO Year | 2019 | 2013 |
| Metric | SLNG | ANIX |
|---|---|---|
| Price | $3.69 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $8.67 |
| AVG Volume (30 Days) | 22.7K | ★ 112.2K |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,245,000.00 | $210,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $14.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $2.44 |
| 52 Week High | $6.36 | $5.46 |
| Indicator | SLNG | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 49.02 |
| Support Level | $3.25 | $2.74 |
| Resistance Level | $4.90 | $3.12 |
| Average True Range (ATR) | 0.33 | 0.17 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 27.48 | 23.05 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.